Can we improve quality of life in asthmatic patients? (The results of a multi-center prospective trial of beclomethasone and fluticasone/salmeterol efficacy in asthmatic patients)

Abstract

The aim of this study was to assess an impact of different anti-inflammatory therapy modes on the quality of life in moderate to severe patients asthma and to choose the most optimal mode of the therapy.

A multi-center prospective comparative study of the therapy with fluticasone+salmeterol (Seretide Multidisk) and beclomethasone was conducted in patients with uncontrolled moderate to severe asthma. The study enrolled 130 patients with severe asthma and 241 patients with moderate persistent asthma. Seretide Multidisk was given to 82 severe asthma patients and 184 moderate asthma patients; beclomethasone was administered to 28 severe asthma patients and 57 those with moderate asthma.

Health-related quality of life was evaluated using the Russian versions of MOS Shot-form 36 -Item (MOS SF-36 ) "Shot-form questionnaire of health status assessment" and the specific Asthma Quality of Life Questionnaire (AQLQ) "Health-related quality of life questionnaire in asthmatic children".

The adequate anti-inflammatory therapy in moderate to severe asthma patients provides decreasing in frequency and severity of asthma symptoms and improves patient’s quality of life. The combined therapy (inhaled corticosteroids and long-acting p2“a 9 ° n'sts) resulted in the most significant improvement in clinical symptoms and general and specific life quality.

The long-term therapy of the asthma (during 12 weeks) makes the patients’ quality of life close to the population norms. The degree of improvement correlates with asthma control level. The most significant approximation of the quality of life to the population norms was achieved using the combined therapy with the inhaled corticosteroid and the long acting p2-agonist (Seretide Multidisk).